GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of “Moderate Buy” from Analysts

GH Research PLC (NASDAQ:GHRS) has been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $34.1111.

Several equities research analysts recently issued reports on GHRS shares. Citigroup reissued a “market outperform” rating on shares of GH Research in a research report on Tuesday, January 6th. Guggenheim reiterated a “buy” rating and set a $29.00 target price on shares of GH Research in a research note on Monday, January 5th. Wall Street Zen downgraded shares of GH Research from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Canaccord Genuity Group lifted their price target on shares of GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Finally, Needham & Company LLC set a $29.00 price objective on shares of GH Research in a research note on Tuesday, January 6th.

GH Research Stock Performance

Shares of GHRS stock opened at $16.73 on Monday. The stock has a market capitalization of $870.46 million, a price-to-earnings ratio of -22.61 and a beta of 0.98. GH Research has a one year low of $7.98 and a one year high of $20.50. The company’s 50-day simple moving average is $14.44 and its 200-day simple moving average is $14.01.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.23). As a group, research analysts forecast that GH Research will post -0.8 EPS for the current year.

Institutional Trading of GH Research

A number of institutional investors and hedge funds have recently made changes to their positions in GHRS. Lynx1 Capital Management LP boosted its position in GH Research by 27.5% during the 3rd quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock valued at $122,997,000 after purchasing an additional 1,854,238 shares during the period. Millennium Management LLC lifted its stake in GH Research by 324.1% in the third quarter. Millennium Management LLC now owns 863,602 shares of the company’s stock valued at $12,350,000 after buying an additional 659,957 shares during the last quarter. HighVista Strategies LLC boosted its holdings in shares of GH Research by 363.0% during the third quarter. HighVista Strategies LLC now owns 241,894 shares of the company’s stock valued at $3,459,000 after acquiring an additional 189,647 shares during the period. CenterBook Partners LP acquired a new position in shares of GH Research during the third quarter valued at $2,376,000. Finally, Stempoint Capital LP bought a new position in shares of GH Research during the second quarter worth about $1,229,000. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.